Clinical deterioration of the Pediatric Cancer Patient using the Early Warning Assessment Scale, Hospital Escuela, 2017-2020
DOI:
https://doi.org/10.5377/hp.v35i1.15546Keywords:
clinical deterioration, Oncology Service Hospital, pediatricsAbstract
Background: events of clinical deterioration are reported in up to 38% of hospitalized pediatric cancer patients.
Objective: To characterize the clinical deterioration of pediatric oncology patients using Early Warning Assessment Scale for Honduras (EVATH).
Methods: retrospective cohort study longitudinal, universe 869 records of pediatric oncology patients hospitalized in the Pediatric Hematology-Oncology Ward of Hospital Escuela in the period from January 2017 to December 2020. Sample size n=124 was determined, with an expected prevalence of 11.8% of deterioration events, confidence level (NC95%) and type II error 5.3%, the selection was probabilistic. For the analysis, descriptive statistics (NC95%) and confidence intervals and p value (<0.05) were determined, in addition to sensitivity, specificity, and negative and positive predictive values.
Results: 12.9% (16/124) presented clinical deterioration. Male patients with deterioration 68.7% (11/16) and without deterioration 50.0% (55/108). Most frequent age 6-12 years patients with deterioration 50.0% (8/16) and without deterioration 39.8% (43/108). No differences between groups according to sex and age (p>0.05). Classification according to EVATH score was low risk patients with deterioration 87.6% (14/16) and without deterioration 100.0% (108/108). With a statistically significant association between groups p=0.001 (RR: 0.17; 95% CI: 0.12-0.25).
Conclusion: 12.95 of the patients presented clinical deterioration, and 68.8% required transfer to Pediatric Intensive Care Unit (PICU) secondary to sepsis/septic shock; with death of almost half of the patients who presented an event of clinical deterioration.
386
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2023 Honduras Pediátrica
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.